Tecentriq-Abraxane Prolongs Survival of Advanced Triple-negative Breast Cancer Patients, Study Shows

Tecentriq-Abraxane Prolongs Survival of Advanced Triple-negative Breast Cancer Patients, Study Shows
Combining Tecentriq (atezolizumab) with the chemotherapy Abraxane (nab-paclitaxel) extends overall survival, and survival without cancer progression, in patients with triple negative breast cancer (TNBC) whose cancer is locally advanced or has spread to distant regions in the body, a Phase 3 clinical trial shows. Combo therapy prolonged patients' overall survival particularly in those with PD-L1 positive tumors, who lived nearly 10 months longer. Also, the treatment was considered well-tolerated, causing no unexpected adverse side effects. The interim results of the study were presented at the European Society for Medical Oncology (ESMO) 2018 Congress held Oct. 19-23 in Munich, Germany. They also were published in the report, “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,” in the journal New England Journal of Medicine. The trial is evaluating the combination of Tecentriq (developed by Genentech-Roche) with the chemotherapy Abraxane as a first-line treatment for metastatic TNBC and locally advanced cancer in patients who cannot undergo surgery. Tecentriq is a blocking antibody that selectively targets PD-L1, belonging to a type of anti-cancer drugs called checkpoint inhibitors. It is approved for some patients with metastatic urothelial carcinoma or non-small cell lung cancer. Abraxane is a standard chemotherapy for patients with metastatic breast cancer, also approved for metastatic non-small cell lung cancer and pancreatic cancer. The combination between both agents is being studied in the IMpassion130 trial (NCT02425891), an international and multicenter, randomized, double-blind Phase 3 study. A total of 902 patients have been enrolled from 41 countries in Europe, the United States and Canada, Asia, Latin Am
Subscribe or to access all post and page content.